Compound index

Growth Hormone Secretagogues & GHRH Analogs

Ipamorelin

Early human trialsInvestigational

Last reviewed: 2026-11-19

Evidence status & limitations

A randomized postoperative bowel-function study did not meet its primary efficacy endpoint; hormone release does not establish other clinical benefits.

Regulatory status

No FDA-approved human medicine for this exact identity was established in this review. Investigational research is not approval.

    Status as of 2026-11-19. Regulations change. Check FDA.gov for current information.

    WADA prohibited status: current list and context

    Known risks & open questions

    FDA notes immune and impurity concerns; rare-event and long-term safety remain uncertain.

    Key sources

    Targeted factual corrections checked against the sources below on November 19, 2026. This is not an exhaustive systematic review; discovery dates, exact molecular forms and current labels require separate verification.

    Related compounds

    • CJC-1295

      Same scientific class · A 29-amino-acid chain. · Early human trials

    • Examorelin

      Same target family · A 6-amino-acid chain. · Early human trials

    • Modified GRF (1–29)

      Same scientific class · A 29-amino-acid chain. · Cell/lab studies only

    • Pralmorelin

      Same target family · A 6-amino-acid chain. · Early human trials

    • Sermorelin

      Same scientific class · A 29-amino-acid chain. · Late-stage human trials

    Related glossary terms